Comparison of Stroke Outcomes of Hub and Spoke Hospital Treated Patients in Mayo Clinic Telestroke Program.
Demaerschalk, Bart M
Comparison of Stroke Outcomes of Hub and Spoke Hospital Treated Patients in Mayo Clinic Telestroke Program. [electronic resource] - Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association Nov 2018 - 2940-2942 p. digital
Publication Type: Comparative Study; Journal Article
1532-8511
10.1016/j.jstrokecerebrovasdis.2018.06.024 doi
Aged
Aged, 80 and over
Anticholesteremic Agents--therapeutic use
Anticoagulants--therapeutic use
Clinical Decision-Making
Delivery of Health Care, Integrated
Disability Evaluation
Female
Fibrinolytic Agents--administration & dosage
Humans
Infusions, Intravenous
Intracranial Hemorrhages--chemically induced
Length of Stay
Male
Middle Aged
Patient Selection
Program Evaluation
Quality Improvement
Quality Indicators, Health Care
Recovery of Function
Retrospective Studies
Risk Factors
Stroke--diagnosis
Telemedicine--methods
Thrombolytic Therapy--adverse effects
Time Factors
Time-to-Treatment
Tissue Plasminogen Activator--administration & dosage
Treatment Outcome
Comparison of Stroke Outcomes of Hub and Spoke Hospital Treated Patients in Mayo Clinic Telestroke Program. [electronic resource] - Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association Nov 2018 - 2940-2942 p. digital
Publication Type: Comparative Study; Journal Article
1532-8511
10.1016/j.jstrokecerebrovasdis.2018.06.024 doi
Aged
Aged, 80 and over
Anticholesteremic Agents--therapeutic use
Anticoagulants--therapeutic use
Clinical Decision-Making
Delivery of Health Care, Integrated
Disability Evaluation
Female
Fibrinolytic Agents--administration & dosage
Humans
Infusions, Intravenous
Intracranial Hemorrhages--chemically induced
Length of Stay
Male
Middle Aged
Patient Selection
Program Evaluation
Quality Improvement
Quality Indicators, Health Care
Recovery of Function
Retrospective Studies
Risk Factors
Stroke--diagnosis
Telemedicine--methods
Thrombolytic Therapy--adverse effects
Time Factors
Time-to-Treatment
Tissue Plasminogen Activator--administration & dosage
Treatment Outcome